CI
NYSE · Health Care
The Cigna Group
$288.06
+4.02 (+1.42%)
CI News30 articles
Blue Cross Blue Shield $2.67B Settlement Payouts Begin in May 2026
Blue Cross Blue Shield settlement payments start in May 2026 for eligible claimants in a $2.67 billion antitrust case. Payouts vary based on claims and premiums, with an estimated average of $333.
Cigna Exits ACA Market, 369,000 Members Need New Plans for 2027
Cigna Group will exit the ACA individual insurance market after 2026, affecting 369,000 members in 11 states who must find new coverage for 2027.
Blue Cross Blue Shield Settlement Payouts to Begin in May
Payments from the $2.67 billion Blue Cross Blue Shield antitrust settlement begin in May 2026 for eligible claimants who filed by November 2021.
UnitedHealth Shares Drop Ahead of Q1 Report, Sector Under Pressure
UnitedHealth Group shares declined sharply Friday, extending weekly losses as the market anticipates first-quarter results. The health insurance sector broadly retreated.
UnitedHealth Gains Amid Medicare Rate Uncertainty and ACA Investigations
UnitedHealth shares edged higher as investors monitored upcoming Medicare Advantage payment decisions and a House Republican probe into ACA insurers. The sector traded mixed.
UnitedHealth Dips After Hours as Medicare Rate Decision Looms
UnitedHealth shares edged lower in extended trading Monday as healthcare stocks underperformed the broader market. Investors are focused on upcoming Medicare Advantage reimbursement updates, with the final rates expected in early April.
Intel Stock Jumps 14% on Apple Foundry Deal: The Real Test Begins
Intel shares surged 13.9% on a reported preliminary chipmaking deal with Apple, but with a $2.44B foundry loss, the real test lies ahead.
Peso Strengthens to 3-Week High as Dollar Weakens Despite Strong US Jobs Data
The Mexican peso surged to a three-week high near 17.19 per dollar on Friday, driven by a weakening dollar even after stronger-than-expected US jobs data. Banxico cut rates by 25 bps to 6.50% and signaled an end to its easing cycle.
Ernexa Therapeutics Surges 60% on Promising Ovarian Cancer Preclinical Data
Ernexa Therapeutics shares jumped about 60% after the company announced its ERNA-101 cell therapy plus PD-1 blockade eliminated tumors and achieved 100% long-term survival in preclinical ovarian cancer models.
Avalo Therapeutics Soars 34% on $375M Offering Following Positive Phase 2 HS Data
Avalo Therapeutics shares surged 34% after pricing a $375M public offering, following positive Phase 2 results for abdakibart in hidradenitis suppurativa. The company aims to fund Phase 3 development.
Netflix, Microsoft, and Others Chart Divergent Cash Strategies
Netflix adds $25B to buybacks after deal breakup; Microsoft plans $190B AI spend. PulteGroup and Mobileye also expand repurchases as stocks dip.
Cabaletta Bio Surges 32% on Early Cell Therapy Data and $150M Financing
Cabaletta Bio shares surged 32% on early cell therapy data and a $150M stock offering. Two of four patients showed clinical activity with rese-cel.
Union Pacific Warns It May Walk Away From $85 Billion Norfolk Southern Deal Amid Regulatory Hurdles
Union Pacific may drop its $85 billion Norfolk Southern merger if regulators require major line sales or trackage rights. The STB is reviewing the revised application.
Palantir Earnings: AI Pricing Power and Growth Under the Microscope
Palantir reports Q1 earnings Monday with options pricing a 9% swing. Focus on AI platform demand, government contracts, and pricing power as analysts diverge.
May Market Turmoil: 5 Inflation Hedges That Hold Their Ground
As oil tops $126 and inflation accelerates, short-term Treasuries, TIPS, gold, silver, and select real assets are proving resilient. The Fed's PCE index rose 3.5% year-over-year in March.
Summit Therapeutics Shares Dive 23% After HARMONi-3 Update Disappoints
Summit Therapeutics shares plummeted 23% after an interim HARMONi-3 update for ivonescimab failed to show early benefit. The trial remains blinded, with final PFS data due in late 2026.
Option Care Health Slumps 28% on Lowered 2026 Revenue View, Chronic Therapy Woes
Option Care Health shares fell 28% after the company lowered its 2026 revenue guidance and reported first-quarter sales that missed Wall Street expectations, citing chronic therapy headwinds.
Soluna Holdings Stock Surges on Sazmining Bitcoin Deal, Then Faces SEC Filing
Soluna Holdings shares rose after Sazmining started a 3MW Bitcoin mining site at Project Dorothy 1B, but an SEC filing for 2.46 million share resale tempers gains.
Phillips 66 Surprises with Q1 Profit as Refining Margins Strengthen
Phillips 66 posted a surprise Q1 adjusted profit of $0.49 per share, beating estimates of a loss, as robust refining margins and 95% utilization offset $839 million in hedge losses. Shares rose over 6%.
Vertiv Completes Strategic Thermal Labs Buyout, Bolstering AI Cooling Portfolio
Vertiv Holdings has closed its acquisition of Strategic Thermal Labs, expanding its AI data-center cooling capabilities. The deal comes amid a 30% Q1 sales surge and an upgraded 2026 forecast.
Oruka Therapeutics Soars on Psoriasis Drug Data, Announces $500M Offering
Oruka Therapeutics shares surged after interim data showed its psoriasis drug ORKA-001 achieved 63.5% complete skin clearance. The company also announced a $500M public offering.
Intellia's CRISPR Therapy for HAE Nears FDA Filing After Late-Stage Success
Intellia Therapeutics (NTLA) announced its CRISPR therapy lonvo-z cut HAE attacks by 87% vs placebo in a Phase 3 trial, with 62% of patients attack-free. A rolling FDA submission has begun.
BitMine's $24M Ethereum Purchase Bolsters 5% Supply Target
BitMine Immersion Technologies bought 10,000 ETH from the Ethereum Foundation for $23.9M, pushing its holdings closer to the 5% supply target as BMNR shares trade near $22.
FBI Probes Crypto Investor Wen Hou's Father Disappearance Amid Fraud Allegations
FBI probes disappearance of Naiping Hou, father of crypto investor Wen Hou, amid cellphone spoofing and fraudulent bank transactions. Soybeans steady despite export sales drop.
Greg Abel Takes the Helm at Berkshire Hathaway's Annual Meeting
Greg Abel will lead Berkshire Hathaway's annual meeting on May 2, facing investor scrutiny over the company's $373B cash pile and underperformance.
CRISPR Therapeutics Shares Slide 11.6% as Casgevy Faces Revenue Test
CRISPR Therapeutics shares fell 11.6% Friday as investors weigh Casgevy's market performance and upcoming governance decisions.
Scinai Immunotherapeutics Soars 82% on $2.61M Private Placement for CDMO Expansion
Scinai Immunotherapeutics shares surged 82% after announcing a $2.61M private placement to support its CDMO expansion and immunotherapy programs.
Norfolk Southern Faces Headwinds from Fuel Costs and Merger Uncertainty
Norfolk Southern reported a 27% drop in Q1 net income to $547 million, weighed by higher fuel costs and merger expenses. Shares slipped 0.5% as investors focused on cost pressures and weak freight volumes.
Regeneron Stock Rises on Drug Pricing Deal, Free Gene Therapy Offer
Regeneron shares gained 2.6% Thursday following a drug-pricing pact with the U.S. and a plan to offer its new gene therapy Otarmeni at no cost. Analysts remain optimistic ahead of Q1 results.
Skillz Surges on $420M Papaya Verdict, Then Tumbles as Reality Sets In
Skillz shares soared 238% on a $420M jury verdict against Papaya Gaming, then dropped 25% pre-market as the market digested the company's $70.4M net loss.